炎症性肠病诊断与治疗的共识意见(2012年·广州)溃疡性结肠炎治疗部分解读

被引:51
作者
杨红
钱家鸣
机构
[1] 中国医学科学院北京协和医学院北京协和医院消化科
关键词
结肠炎,溃疡性; 治疗; 氨基水杨酸类; 糖皮质激素类; 免疫抑制剂; 生物制剂;
D O I
暂无
中图分类号
R574.62 [结肠疾病];
学科分类号
100201 [内科学];
摘要
溃疡性结肠炎(UC)是一种病因尚不十分清楚的慢性非特异性肠道炎症性疾病,近十余年来国内就诊人数呈逐步增加趋势。2012年,中华医学会消化病学分会炎症性肠病(IBD)学组对2007年版中国IBD诊治共识进行了修订。本文以本次共识意见为基础,解读共识意见中建议的精髓,剖析UC治疗中需注意的要点,分层阐述氨基水杨酸制剂、糖皮质激素、免疫抑制剂、生物制剂在UC治疗中的新进展,以期提高临床医师对UC治疗的认知水平。
引用
收藏
页码:724 / 727
页数:4
相关论文
共 8 条
[1]
European evidence-based Consensus on the management of ulcerative colitis: Current management [J].
Travis, S. P. L. ;
Stange, E. F. ;
Lemann, M. ;
Oresland, T. ;
Bemelman, W. A. ;
Chowers, Y. ;
Colombel, J. F. ;
D'Haens, G. ;
Ghosh, S. ;
Marteau, P. ;
Kruis, W. ;
Mortensen, N. J. Mcc. ;
Penninckx, F. ;
Gassull, M. .
JOURNAL OF CROHNS & COLITIS, 2008, 2 (01) :24-62
[2]
<ce:link locator="fx1"/> Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression.[J].Dan Turner;Catharine M. Walsh;A. Hillary Steinhart;Anne M. Griffiths.Clinical Gastroenterology and Hepatology.2007, 1
[3]
Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial [J].
Oren, R ;
Arber, N ;
Odes, S ;
Moshkowitz, M ;
Keter, D ;
Pomeranz, I ;
Ron, Y ;
Reisfeld, I ;
Broide, E ;
Lavy, A ;
Fich, A ;
Eliakim, R ;
Patz, J ;
Bardan, E ;
Villa, Y ;
Gilat, T .
GASTROENTEROLOGY, 1996, 110 (05) :1416-1421
[4]
HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF ACTIVE ULCERATIVE-COLITIS [J].
ROSENBERG, W ;
IRELAND, A ;
JEWELL, DP .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1990, 12 (01) :40-41
[5]
COMPARISON OF CORTICOSTEROID AND SULPHASALAZINE THERAPY IN ULCERATIVE COLITIS [J].
TRUELOVE, SC ;
DRAPER, G ;
WATKINSON, G .
BMJ-BRITISH MEDICAL JOURNAL, 1962, (5321) :1708-+
[6]
Out-Patient Treatment Of Ulcerative Colitis: Comparison Between Three Doses Of Oral Prednisone.[J].J. H. Baron;A. M. Connell;T. G. Kanaghinis;J. E. Lennard-Jones;F. Avery Jones.The British Medical Journal.1962, 5302
[7]
中国炎症性肠病诊断治疗规范的共识意见.[J]..中华内科杂志.2008, 01
[8]
5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease [J].
Cheng, Yang ;
Desreumaux, Pierre .
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (03) :309-314